Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

770.42
-16.6200-2.11%
Volume:364.99K
Turnover:283.98M
Market Cap:81.45B
PE:18.52
High:791.05
Open:782.45
Low:769.97
Close:787.04
52wk High:821.11
52wk Low:476.49
Shares:105.72M
Float Shares:103.30M
Volume Ratio:0.64
T/O Rate:0.35%
Dividend:3.52
Dividend Rate:0.46%
EPS(TTM):41.59
EPS(LYR):41.48
ROE:14.87%
ROA:5.91%
PB:2.61
PE(LYR):18.57

Loading ...

Regeneron, Sanofi announce FDA approval of Dupixent for AFRS

TIPRANKS
·
Yesterday

FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older

Reuters
·
Yesterday

Sanofi - Phase 3 Study Shows Dupixent Reduces Nasal Signs and Symptoms

THOMSON REUTERS
·
Yesterday

Sanofi - Approval Expands Our Approved Indications in Sino-Nasal Diseases to NOW Include Afrs, Alongside Chronic Rhinosinusitis With Nasal Polyps

THOMSON REUTERS
·
Yesterday

Press Release: Sanofi and Regeneron’s Dupixent Approved in the US as the First and Only Medicine for Allergic Fungal Rhinosinusitis

THOMSON REUTERS
·
Yesterday

Regeneron Director Huda Y. Zoghbi Disposes of Common Shares

Reuters
·
Yesterday

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850, Maintains Outperform Rating

MT Newswires Live
·
Feb 20

Garetosmab Biologics License Application Accepted For FDA Priority Review

Reuters
·
Feb 19

FDA accepts Regeneron’s garetosmab BLA for priority review in FOP

Reuters
·
Feb 19

Regeneron Pharmaceuticals Inc - FDA Decision Expected by August 2026

THOMSON REUTERS
·
Feb 19

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

GlobeNewswire
·
Feb 19

Citi Reaffirms Their Buy Rating on Regeneron (REGN)

TIPRANKS
·
Feb 19

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Feb 18

Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)

TIPRANKS
·
Feb 17

Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's Eylea

Reuters
·
Feb 17

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Reuters
·
Feb 17

Regeneron Advances REGN7508 Into Phase 3 To Tackle Cancer-Linked Blood Clots

TIPRANKS
·
Feb 14

HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating

MT Newswires Live
·
Feb 13

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Benzinga
·
Feb 13

Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant

Reuters
·
Feb 12